MIRO - Miromatrix gets US patent for recellularizing technology for use in organ transplant

• Miromatrix Medical ( NASDAQ: MIRO ) said it has received a new patent from the U.S. Patent and Trademark Office for its perfusion decellularization and recellularization technology.
• The patent number 11,414,644 titled 'Methods of Recellularizing a Tissue or Organ for Improved Transplantability' covers the revascularization of decellularized organs and tissues which include all types of organs including liver, lung, kidney, and heart.
• The new patent expands the company's patent portfolio covering the bioengineering of transplantable organs, Miromatrix said in an Aug. 25 press release.

For further details see: